Indeed, CEBPB and EP300, along with genes related to the Mitogen-Activated Protein Kinase (MAPK) signaling cascade such as MAP3K1, MAP2K2, and MAP3K11 were significantly upregulated in RMC tumor cells following treatment with nivolumab plus ipilimumab, (Fig. 2f). This evidence concerns the gene MAP3K11 and neoplasm.